Respiratory Syncytial Virus (RSV) is a leading cause of severe respiratory illness in infants. Pregnant women living with HIV and their babies represent a particularly vulnerable group. Dr. Sehulong Robert Moraba served as the Principal Investigator for a critical Phase 3 trial (C3671032) evaluating the safety and immunogenicity of an RSV Prefusion F subunit vaccine in this population.
This pivotal study, with SAHPRA reference 20231125, aimed to protect both mothers and their newborns through maternal immunization. As Principal Investigator at Setshaba Research Centre, Dr. Moraba was responsible for the overall conduct, safety oversight, and scientific integrity of the trial, ensuring that this potentially life-saving intervention was thoroughly evaluated for a group that stands to benefit immensely.
